Nightstar Therapeutics to Present at 2018 Cell & Gene Meeting on the Mesa

WALTHAM, Mass. and LONDON, Oct. 01, 2018 (GLOBE NEWSWIRE) -- Nightstar Therapeutics plc NITE, a clinical-stage gene therapy company developing treatments for rare inherited retinal diseases, today announced that the company plans on presenting at the Cell & Gene Meeting on the Mesa organized by the Alliance for Regenerative Medicine and the Sanford Stem Cell Clinical Center at UC San Diego, on Wednesday October 3, 2018 at 5:15pm PDT in La Jolla, California.

To access the live webcast, please visit ir.nightstartx.com. A replay of the webcast will be available on the Nightstar website for two weeks following the conference.

About Nightstar

Nightstar is a leading clinical-stage gene therapy company focused on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases that would otherwise progress to blindness. Nightstar's lead product candidate, NSR-REP1, is currently in Phase 3 development for the treatment of patients with choroideremia, a rare, degenerative, genetic retinal disorder that has no current treatments. Results from a Phase 1/2 trial of NSR-REP1 were published in The Lancet in 2014 and in The New England Journal of Medicine in 2016. Nightstar's second product candidate, NSR-RPGR, is currently being evaluated in a Phase 1/2 clinical trial for the treatment of patients with X-linked retinitis pigmentosa, an inherited X-linked recessive retinal disease.

For more information about Nightstar or its clinical trials, please visit www.nightstartx.com.

Contact:

Senthil Sundaram, Chief Financial Officer

Brian Luque, Sr. Manager, Investor Relations

investors@nightstartx.com

nightstar logo.png

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: NewsPress Releases
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!